Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000425897

Medchemexpress LLC AZP-531 | 1088543-62-7 | 99.8% | 962.02 | 10 MG
SDP

Catalog No. 5000425897
Encompass_Preferred

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight. It exerts survival effects on pancreatic b-cells and human pancreatic islets comparable to unacylated ghrelin (UAG). It is very stable in human plasma in vitro with no degradation observed after 1 day of incubation at 37°C.

  • Prevents body weight increase caused by a high-fat diet in mice
  • Prevents high-fat diet-induced proinflammatory effects
  • Stimulates mitochondrial function markers in brown adipose tissue
  • Prevents the development of a prediabetic metabolic state
  • Prevents a high-fat diet-induced increase in acyl ghrelin levels
  • Significantly improves glucose concentrations without increasing insulin levels
  • Decreases mean body weight by 2.6 kg (vs 0.8 kg for placebo)
  • Reduces HbA1c by 0.4% (vs 0.2% for placebo)

Catalog No. 50-004-25897 Supplier Medchemexpress LLC Supplier No. HYP023110MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

AZP-531 is an analogue of unacylated ghrelin designed to improve glycaemic control and reduce weight. It exerts survival effects on pancreatic b-cells and human pancreatic islets comparable to unacylated ghrelin (UAG). It is very stable in human plasma in vitro with no degradation observed after 1 day of incubation at 37°C.

  • Prevents body weight increase caused by a high-fat diet in mice
  • Prevents high-fat diet-induced proinflammatory effects
  • Stimulates mitochondrial function markers in brown adipose tissue
  • Prevents the development of a prediabetic metabolic state
  • Prevents a high-fat diet-induced increase in acyl ghrelin levels
  • Significantly improves glucose concentrations without increasing insulin levels
  • Decreases mean body weight by 2.6 kg (vs 0.8 kg for placebo)
  • Reduces HbA1c by 0.4% (vs 0.2% for placebo)

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.